dexmedetomidine + saline

IN-DEX + saline is a clinical trial designation for the intranasal administration of dexmedetomidine, a selective alpha-2 adrenoceptor agonist, used in conjunction with a saline placebo in a crossover study design. Sponsored by the Dayton VA Medical Center, this regimen was evaluated in a Phase 4 trial (NCT02773797) to assess the safety and efficacy of intranasal dexmedetomidine for inducing light to moderate sedation in patients with severe Chronic Obstructive Pulmonary Disease (COPD). Dexmedetomidine is a non-narcotic sedative that provides anxiolysis and analgesia without the respiratory depression typically associated with opioids or benzodiazepines, making it a candidate for managing breathlessness and anxiety in high-risk respiratory patients.

Other names

IN-DEX + salineintranasal dexmedetomidine